Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ebenhan, Thomas ^a,b   Gheysens, Olivier ^c   Kruger, Hendrick Gert ^b   Zeevaart, Jan Rijn ^d   Sathekge, Mike Machaba ^a  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TRACER; ANTIMICROBIAL CATIONIC PEPTIDE; RADIOPHARMACEUTICAL AGENT;

BACTERIAL CELL; CELL SPECIFICITY; CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HYDROPHOBICITY; INFECTION; MOLECULAR IMAGING; MOLECULAR INTERACTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BACTERIAL INFECTIONS; MOUSE;

BACTERIA (MICROORGANISMS); EUKARYOTA; MAMMALIA;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; HUMANS; MICE; MOLECULAR IMAGING; RADIOPHARMACEUTICALS;

EID: 84930333296     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/867381     Document Type: Review

References (71)

1. L. J. Higgins and M. G. Pomper, "The evolution of imaging in cancer: Current state and future challenges," Seminars in Oncology, vol. 38, no. 1, pp. 3-15, 2011.
2. S. Basu, T. Chryssikos, S. Moghadam-Kia, H. Zhuang, D. A. Torigian, and A. Alavi, "Positron emission tomography as a diagnostic tool in infection: Present role and future possibilities," Seminars in Nuclear Medicine, vol. 39, no. 1, pp. 36-51, 2009.
3. C. J. Palestro, "Radionuclide imaging of infection: In search of the grail," Journal of Nuclear Medicine, vol. 50,no. 5, pp.671-673, 2009.
4. H. J. J. M. Rennen, O. C. Boerman, W. J. G. Oyen, and F. H. M. Corstens, "Imaging infection/inflammation in the new millennium," European Journal of NuclearMedicine, vol. 28, no. 2, pp. 241-252, 2001.
5. O. C. Boerman, E. T.M. Dams,W. J.G.Oyen, F. H.M. Corstens, and G. Storm, "Radiopharmaceuticals for scintigraphic imaging of infection and inflammation," Inflammation Research, vol. 50, no. 2, pp. 55-64, 2001.
6. A. Signore, M. Chianelli, C. D'Alessandria, and A. Annovazzi, "Receptor targeting agents for imaging infammatin/infection: Where are we now?" Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 3, pp. 236-242, 2006.
7. S. J. Goldsmith and S. Vallabhajosula, "Clinically proven radiopharmaceuticals for infection imaging: Mechanisms and applications," Seminars in Nuclear Medicine, vol. 39, no. 1, pp. 2-10, 2009.
8. C. P. J. M. Brouwer, M. Wulferink, and M. M. Welling, "The pharmacology of radiolabeled cationic antimicrobial peptides," Journal of Pharmaceutical Sciences, vol. 97, no. 5, pp. 1633-1651, 2008.
9. M. R. Yeaman and N. Y. Yount, "Mechanisms of antimicrobial peptide action and resistance," Pharmacological Reviews, vol. 55, no. 1, pp. 27-55, 2003.
10. S. M. Okarvi, "Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases," Medicinal Research Reviews, vol. 24, no. 3, pp. 357-397, 2004.
11. E. Guaní-Guerra, T. Santos-Mendoza, S. O. Lugo-Reyes, and L. M. Terán, "Antimicrobial peptides: General overview and clinical implications in human health and disease," Clinical Immunology, vol. 135, no. 1, pp. 1-11, 2010.
12. M. Zasloff, "Antimicrobial peptides ofmulticellular organisms," Nature, vol. 415, no. 6870, pp. 389-395, 2002.
13. D. Takahashi, S. K. Shukla, O. Prakash, and G. Zhang, "Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity," Biochimie, vol. 92, no. 9, pp. 1236-1241, 2010.
14. I. Zelezetsky and A. Tossi, "Alpha-helical antimicrobial peptides-using a sequence template to guide structure-activity relationship studies," Biochimica et Biophysica Acta, vol. 1758, no. 9, pp. 1436-1449, 2006.
15. R. M. Epand and H. J. Vogel, "Diversity of antimicrobial peptides and their mechanisms of action," Biochimica et Biophysica Acta, vol. 1462, no. 1-2, pp. 11-28, 1999.
16. L. Zhang, A. Rozek, and R. E. W. Hancock, "Interaction of cationic antimicrobial peptides with model membranes," The Journal of Biological Chemistry, vol. 276, no. 38, pp. 35714-35722, 2001.
17. A. Tossi, L. Sandri, and A. Giangaspero, "Amphipathic, alphahelical antimicrobial peptides," Biopolymers, vol. 55, no. 1, pp. 4-30, 2000.
18. M. Dathe and T. Wieprecht, "Structural features of helical antimicrobial peptides: Their potential to modulate activity on model membranes and biological cells," Biochimica et Biophysica Acta-Biomembranes, vol. 1462, no. 1-2, pp. 71-87, 1999.
19. M. A. Kol, A. I. P. M. de Kroon, D. T. S. Rijkers, J. A. Killian, and B. De Kruijff, "Membrane-spanning peptides induce phospholipid flop: Amodel for phospholipid translocation across the inner membrane of E. coli," Biochemistry, vol. 40, no. 35, pp. 10500-10506, 2001.
20. M. M. Welling, A. Lupetti, H. S. Balter et al., "99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections," Journal of Nuclear Medicine, vol. 42, no. 5, pp. 788-794, 2001.
21. N. Y. Yount and M. R. Yeaman, "Multidimensional signatures in antimicrobial peptides," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 19, pp. 7363-7368, 2004.
22. N. Sitaram and R. Nagaraj, "Interaction of antimicrobial peptides with biological and model membranes: Structural and charge requirements for activity," Biochimica et Biophysica Acta: Biomembranes, vol. 1462, no. 1-2, pp. 29-54, 1999.
23. M. Dathe, H. Nikolenko, J. Meyer, M. Beyermann, and M. Bienert, "Optimization of the antimicrobial activity of magainin peptides by modification of charge," FEBS Letters, vol. 501, no. 1-3, pp. 146-150, 2001.
24. Y. Shai, "Mode of action of membrane active antimicrobial peptides," Biopolymers, vol. 66, no. 4, pp. 236-248, 2002.
25. T. Wieprecht, M. Dathe, M. Beyermann et al., "Peptide hydrophobicity controls the activity and selectivity ofmagainin 2 amide in interaction with membranes," Biochemistry, vol. 36, no. 20, pp. 6124-6132, 1997.
26. N. Uematsu and K.Matsuzaki, "Polar angle as a determinant of amphipathic α-helix-lipid interactions: A model peptide study," Biophysical Journal, vol. 79, no. 4, pp. 2075-2083, 2000.
27. K. Matsuzaki, "Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes," Biochimica et Biophysica Acta-Biomembranes, vol. 1462, no. 1-2, pp. 1-10, 1999.
28. T. Ganz, "Defensins: Antimicrobial peptides of innate immunity," Nature Reviews Immunology, vol. 3, no. 9, pp. 710-720, 2003.
29. L.V.Collins, S. A.Kristian,C.Weidenmaier et al., "Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice," The Journal of Infectious Diseases, vol. 186, no. 2, pp. 214-219, 2002.
30. M. Gross, S. E. Cramton, F. Götz, and A. Peschel, "Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces," Infection and Immunity, vol. 69, no. 5, pp. 3423-3426, 2001.
31. A. Peschel, "How do bacteria resist human antimicrobial peptides?" Trends in Microbiology, vol. 10, no. 4, pp. 179-186, 2002.
32. K. Matsuzaki, "Control of cell selectivity of antimicrobial peptides," Biochimica et Biophysica Acta, vol. 1788, no. 8, pp. 1687-1692, 2009.
33. W. L. Maloy and U. P. Kari, "Structure-activity studies on magainins and other host defense peptides," Biopolymers, vol. 37, no. 2, pp. 105-122, 1995.
34. E. Breukink, I. Wiedemann, C. van Kraaij, O. P. Kuipers, H.-. Sahl, and B. de Kruijff, "Use of the cell wail precursor lipid II by a pore-forming peptide antibiotic," Science, vol. 286, no. 5448, pp. 2361-2364, 1999.
35. I.Wiedemann, E. Breukink, C. van Kraaij et al., "Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity," The Journal of Biological Chemistry, vol. 276, no. 3, pp. 1772-1779, 2001.
36. S. E. Blondelle, K. Lohner, and M. Aguilar, "Lipid-induced conformation and lipid-binding properties of cytolytic and antimicrobial peptides: Determination and biological specificity," Biochimica et Biophysica Acta: Biomembranes, vol. 1462, no. 1-2, pp. 89-108, 1999.
37. L. H. Kondejewski, M. Jelokhani-Niaraki, S. W. Farmer et al., "Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity," The Journal of Biological Chemistry, vol. 274, no. 19, pp. 13181-13192, 1999.
38. L. Yang, T. M. Weiss, R. I. Lehrer, and H. W. Huang, "Crystallization of antimicrobial pores in membranes: Magainin and protegrin," Biophysical Journal, vol. 79, no. 4, pp. 2002-2009, 2000.
39. H. W. Huang, "Action of antimicrobial peptides: Two-state model," Biochemistry, vol. 39, no. 29, pp. 8347-8352, 2000.
40. K. A. HenzlerWildman, D. Lee, and A. Ramamoorthy, "Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37," Biochemistry, vol. 42, no. 21, pp. 6545-6558, 2003.
41. J. M. Sanderson, "Peptide-lipid interactions: Insights and perspectives," Organic & Biomolecular Chemistry, vol. 3, no. 2, pp. 201-212, 2005.
42. L. Yang, T. A. Harroun, T. M.Weiss, L. Ding, and H.W. Huang, "Barrel-stavemodel or toroidalmodel?Acase study onmelittin pores," Biophysical Journal, vol. 81, no. 3, pp. 1475-1485, 2001.
43. B. Circiumaru, G. Baldock, and J. A. Cohen, "A prospective study of fever in the intensive care unit," Intensive Care Medicine, vol. 25, no. 7, pp. 668-673, 1999.
44. W. Becker and J. Meller, "The role of nuclear medicine in infection and inflammation," TheLancet Infectious Diseases, vol. 1, no. 5, pp. 326-333, 2001.
45. A. Lupetti, P. H. Nibbering, M. M.Welling, and E. K. J. Pauwels, "Radiopharmaceuticals: New antimicrobial agents," Trends in Biotechnology, vol. 21, no. 2, pp. 70-73, 2003.
46. L.Meléndez-Alafort, J. Rodríguez-Cortés, G. Ferro-Flores et al., "Biokinetics of 99mTc-UBI 29-41 in humans," Nuclear Medicine and Biology, vol. 31, no. 3, pp. 373-379, 2004.
47. L.Meléndez-Alafort, F.D. M. Ramírez, G. Ferro-Flores, C. A. de Murphy,M. Pedraza-López, and D. J. Hnatowich, "Lys and Arg in UBI: A specific site for a stable Tc-99m complex?" Nuclear Medicine and Biology, vol. 30, no. 6, pp. 605-615, 2003.
48. D.Blok, R. I. J. Feitsma, P. Vermeij, and E. J.K.Pauwels, "Peptide radiopharmaceuticals in nuclear medicine," European Journal of Nuclear Medicine, vol. 26, no. 11, pp. 1511-1519, 1999.
49. P. S.Hiemstra, M. T. van den Barselaar, M. Roest, P. H. Nibbering, and R. van Furth, "Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages," Journal of Leukocyte Biology, vol. 66, no. 3, pp. 423-428, 1999.
50. G. Ferro-Flores, C. Arteaga De Murphy, M. Pedraza-López et al., "In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria," Nuclear Medicine and Biology, vol. 30, no. 6, pp. 597-603, 2003.
51. M. M. Welling, A. Paulusma-Annema, H. S. Balter, E. K. J. Pauwels, and P. H. Nibbering, "Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations," European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 292-301, 2000.
52. M. S. Akhtar, A. Qaisar, J. Irfanullah et al., "Antimicrobial peptide 99mTc-Ubiquicidin 29-41 as human infection-imaging agent: Clinical trial," Journal of Nuclear Medicine, vol. 46, no. 4, pp. 567-573, 2005.
53. K. A. Brogden, "Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria?" Nature Reviews Microbiology, vol. 3, no. 3, pp. 238-250, 2005.
54. C. A. deMurphy, F. Gemmel, and J. Balter, "Clinical trial of specific imaging of infections," Nuclear Medicine Communications, vol. 31, no. 8, pp. 726-733, 2010.
55. S. Saeed, J. Zafar, B. Khan et al., "Utility of 99mTc-labelled antimicrobial peptide ubiquicidin (29-41) in the diagnosis of diabetic foot infection," European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 5, pp. 737-743, 2013.
56. K. Aryana, A. Hootkani, R. Sadeghi et al., "99mTc-labeled Ubiquicidin scintigraphy: A promisingmethod in hip prosthesis infection diagnosis," NuklearMedizin, vol. 51, no. 4, pp. 133-139, 2012.
57. D. Beiki, G. Yousefi, B. Fallahi et al., "99mtc-Ubiquicidin [29-41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation," Iranian Journal of Pharmaceutical Research, vol. 12, no. 2, pp. 347-353, 2013.
58. B. Nazari, Z. Azizmohammadi,M. Rajaei et al., "Role of99mTcubiquicidin 29-41 scintigraphy to monitor antibiotic therapy in patients with orthopedic infection: A preliminary study," Nuclear Medicine Communications, vol. 32, no. 8, pp. 745-751, 2011.
59. M. Assadi, K. Vahdat, I. Nabipour et al., "Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging," Nuclear Medicine Communications, vol. 32, no. 8, pp. 716-723, 2011.
60. C. Dillmann-Arroyo, R. Cantú-Leal, H. Campa-Núñez, C. López-Cavazos, M. Bermúdez-Argüelles, and J. C. Mejía-Herrera, "Application of the ubiquicidin 29-41 scan in the diagnosis of pyogenic vertebral osteomyelitis," Acta Ortopédica Mexicana, vol. 25, no. 1, pp. 27-31, 2011.
61. A. M. Taghizadeh, M. H. Mandegar, and M. Assadi, "Technetium-99m-ubiquicidin scintigraphy in the detection of infective endocarditis," Hellenic Journal of Nuclear Medicine, vol. 17, no. 1, pp. 47-48, 2014.
62. M. Fani, J. P. andré, and H. R.Maecke, "68Ga-PET: A powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals," Contrast Media & Molecular Imaging, vol. 3, no. 2, pp. 67-77, 2008.
63. T. Ebenhan, N. Chadwick, M. M. Sathekge et al., "Peptide synthesis, characterization and 68Ga-radiolabeling of NOTAconjugated ubiquicidin fragments for prospective infection imaging with PET/CT," Nuclear Medicine and Biology, vol. 41, no. 5, pp. 390-400, 2014.
64. T. Ebenhan, J. R. Zeevaart, J. D. Venter et al., "Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging," Journal of Nuclear Medicine, vol. 55, no. 2, pp. 308-314, 2014.
65. B. Agerberth, J. Charo, J.Werr et al., "The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations," Blood, vol. 96, no. 9, pp. 3086-3093, 2000.
66. D. Salber, J. Gunawan, K. J. Langen et al., "Comparison of 99mTc-and 18F-ubiquicidin autoradiography to anti-Staphylococcus aureus immunofluorescence in rat muscle abscesses," Journal of Nuclear Medicine, vol. 49, no. 6, pp. 995-999, 2008.
67. L.Dijkshoorn, C. P. J. M. Brouwer, S. J. P. Bogaards, A.Nemec, P. J. Van Den Broek, and P. H. Nibbering, "The synthetic n-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrugresistant Acinetobacter baumannii," Antimicrobial Agents and Chemotherapy, vol. 48, no. 12, pp. 4919-4921, 2004.
68. C. P. J. M. Brouwer, M. Rahman, and M. M.Welling, "Discovery and development of a synthetic peptide derived fromlactoferrin for clinical use," Peptides, vol. 32, no. 9, pp. 1953-1963, 2011.
69. A. Won, A. Ruscito, and A. Ianoul, "Imaging the membrane lytic activity of bioactive peptide latarcin 2a," Biochimica et Biophysica Acta-Biomembranes, vol. 1818, no. 12, pp. 3072-3080, 2012.
70. X. Chen, E. Sievers, Y. Hou et al., "Integrin αvβ3-targeted imaging of lung cancer," Neoplasia, vol. 7, no. 3, pp. 271-279, 2005.
71. P. H. Nibbering, M. M. Welling, A. Paulusma-Annema, C. P. J. M. Brouwer, A. Lupetti, and E. K. J. Pauwels, "99mTc-labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus," Journal of Nuclear Medicine, vol. 45, no. 2, pp. 321-326, 2004.